Free Trial

LifeStance Health Group (LFST) Stock Forecast & Price Target

LifeStance Health Group logo
$7.48 -0.27 (-3.48%)
(As of 12/17/2024 ET)

LifeStance Health Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
1
Buy
3

Based on 5 Wall Street analysts who have issued ratings for LifeStance Health Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 1 has given a sell rating, 1 has given a hold rating, and 3 have given a buy rating for LFST.

Consensus Price Target

$8.70
16.31% Upside
According to the 5 analysts' twelve-month price targets for LifeStance Health Group, the average price target is $8.70. The highest price target for LFST is $10.00, while the lowest price target for LFST is $7.00. The average price target represents a forecasted upside of 16.31% from the current price of $7.48.
Get the Latest News and Ratings for LFST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for LifeStance Health Group and its competitors.

Sign Up

LFST Analyst Ratings Over Time

TypeCurrent Forecast
12/19/23 to 12/18/24
1 Month Ago
11/19/23 to 11/18/24
3 Months Ago
9/20/23 to 9/19/24
1 Year Ago
12/19/22 to 12/19/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.70$8.50$8.25$8.25
Forecasted Upside16.31% Upside21.26% Upside20.26% Upside11.19% Upside
Consensus Rating
Hold
Hold
Hold
Hold

LFST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LFST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

LifeStance Health Group Stock vs. The Competition

TypeLifeStance Health GroupMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside16.31% Upside28,675.54% Upside12.02% Upside
News Sentiment Rating
Positive News

See Recent LFST News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/16/2024The Goldman Sachs Group
2 of 5 stars
J. Perse
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$10.00+39.47%
11/11/2024Barclays
3 of 5 stars
 Boost TargetUnderweight ➝ Underweight$6.00 ➝ $7.00-2.91%
8/15/2024UBS Group
4 of 5 stars
 Lower TargetNeutral ➝ Neutral$9.00 ➝ $7.50+26.69%
4/22/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $10.00+69.20%
3/6/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$8.00 ➝ $9.00+23.12%
11/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$10.00 ➝ $8.00+29.87%
5/15/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$8.00 ➝ $9.00+5.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:17 AM ET.


LFST Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for LifeStance Health Group is $8.70, with a high forecast of $10.00 and a low forecast of $7.00.

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LifeStance Health Group in the last twelve months. There is currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" LFST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LFST, but not buy additional shares or sell existing shares.

According to analysts, LifeStance Health Group's stock has a predicted upside of 16.31% based on their 12-month stock forecasts.

Over the previous 90 days, LifeStance Health Group's stock had 1 upgrade by analysts.

LifeStance Health Group has been rated by research analysts at Barclays, and The Goldman Sachs Group in the past 90 days.

Analysts like LifeStance Health Group less than other "medical" companies. The consensus rating for LifeStance Health Group is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LFST compares to other companies.


This page (NASDAQ:LFST) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners